


RSC Drug Discovery

Edited by Lyn H Jones and Andrew J McKnight

Biotherapeutics

Recent Developments using
Chemical and Molecular Biology



RSC Publishing

Biotherapeutics

Recent Developments using Chemical and Molecular Biology

Edited by

Lyn H. Jones

Pfizer R&D

WorldWide Medicinal Chemistry

Cambridge, MA

USA

Email: lyn.jones@pfizer.com

and


Andrew J. McKnight

AnaptysBio, Inc.

San Diego, CA

USA

Email: amcknight@anaptysbio.com



RSC Publishing

RSC Drug Discovery Series No. 36

ISBN: 978-1-84973-601-5

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2013

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

The RSC is not responsible for individual opinions expressed in this work.

Published by The Royal Society of Chemistry,
Thomas Graham House, Science Park, Milton Road,
Cambridge CB4 0WF, UK

Registered Charity Number 207890

For further information see our web site at www.rsc.org

Biotherapeutics

Recent Developments using Chemical and Molecular Biology

RSC Drug Discovery Series

Editor-in-Chief:

Professor David Thurston, *King's College, London, UK*

Series Editors:

Dr David Fox, *Vulpine Science and Learning, UK*

Professor Ana Martinez, *Medicinal Chemistry Institute-CSIC, Madrid, Spain*

Professor David Rotella, *Montclair State University, USA*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- | | |
|---|---|
| 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups | 21: Designing Multi-Target Drugs |
| 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1 | 22: Nanostructured Biomaterials for Overcoming Biological Barriers |
| 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2 | 23: Physico-Chemical and Computational Approaches to Drug Discovery |
| 4: Accounts in Drug Discovery | 24: Biomarkers for Traumatic Brain Injury |
| 5: New Frontiers in Chemical Biology | 25: Drug Discovery from Natural Products |
| 6: Animal Models for Neurodegenerative Disease | 26: Anti-Inflammatory Drug Discovery |
| 7: Neurodegeneration | 27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules |
| 8: G Protein-Coupled Receptors | 28: Drug Discovery for Psychiatric Disorders |
| 9: Pharmaceutical Process Development | 29: Organic Chemistry of Drug Degradation |
| 10: Extracellular and Intracellular Signaling | 30: Computational Approaches to Nuclear Receptors |
| 11: New Synthetic Technologies in Medicinal Chemistry | 31: Traditional Chinese Medicine |
| 12: New Horizons in Predictive Toxicology | 32: Successful Strategies for the Discovery of Antiviral Drugs |
| 13: Drug Design Strategies: Quantitative Approaches | 33: Comprehensive Biomarker Discovery and Validation for Clinical Application |
| 14: Neglected Diseases and Drug Discovery | 34: Emerging Drugs and Targets for Parkinson's Disease |
| 15: Biomedical Imaging | 35: Pain Therapeutics; Current and Future Treatment Paradigms |
| 16: Pharmaceutical Salts and Cocrystals | 36: Biotherapeutics: Recent Developments using Chemical and Molecular Biology |
| 17: Polyamine Drug Discovery | |
| 18: Proteinases as Drug Targets | |
| 19: Kinase Drug Discovery | |
| 20: Drug Design Strategies: Computational Techniques and Applications | |

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,

Email: booksales@rsc.org

Visit our website at www.rsc.org/books

Preface

Biotherapeutic modalities are often considered beyond the reach of the medicinal chemist. The language and terminology can differ significantly between small and large molecule drug discovery, and yet the aims are essentially the same. We believe chemistry has an essential role in the future success of this exciting area, and this book was conceived as an attempt to illustrate the successful partnership of chemical and molecular biology to enable and advance biotherapeutics (so-called ‘chemologics’).

The design–synthesis–screen–design cycle, an engine for successful small molecule drug discovery, is not usually a component of biotherapeutic discovery, yet our challenge to this community is that that need not be the case – a deeper molecular understanding should be brought to bear in the biotherapeutics field, such that the empiricism that currently persists can be addressed. The challenge will be to generate knowledge and apply those learnings prospectively to avoid making the same mistakes and accelerate our decision making – the delineation of structure–function or structure–toxicology relationships will find increasing value in the biotherapeutic space. Small molecule drug discovery has already evolved past the period of ‘make lots of stuff, screen lots of stuff, and see what pops out!’ It is neither inspiring nor cost effective – design strategies are now far more sophisticated, augmented significantly by advances in biophysical techniques, computational sciences and the accuracy of predictive *in silico* tools. Our belief is that these methods will be harnessed to a greater extent in the advancement of biotherapeutic discovery and optimization approaches in the future.

This book approaches the huge area of biotherapeutics from the perspective of improved *molecular design*, which draws from the synergies between chemical biology, medicinal chemistry and molecular biology in particular. Recent developments in these disciplines that have delivered drugs, clinical candidates or significantly advanced biotherapeutic discovery and design will

be described. A broad range of modalities are highlighted that will appeal to those working in a number of biomolecular areas (oligonucleotides, sugars, proteins and peptides). The chapters, written by an impressive list of world experts in their respective fields, detail a number of diverse therapeutic opportunities, including immunopharmacotherapy, optimized fully human or humanized antibodies, bicyclic peptide phage libraries, synthetic proteins and vaccines, micro-RNA, bacterial toxins, stabilized cyclotides, antibody–drug conjugates, peptide epitope mimicry and synthetic immunology.

Additionally, we believe this book will serve as inspiration for the medicinal chemistry community, particularly when presented with examples of how their expertise can make considerable impact in the biotherapeutics arena. Much has been made of the need to choose the ‘best target’ in drug discovery, but as much emphasis should then be placed on choosing the ‘best modality’, really, our approach should be ‘modality agnostic’.

Our vision is that all biopharmaceutical chemists, whether in industry or academia, are equipped with capabilities both in small and large molecule drug discovery (and as a minimum can speak the language of, and engage in, ‘biotherapies’) and we hope this book will help towards that goal. In some ways, this book is a call to the traditional small molecule medicinal chemistry community to ask broader questions of their projects and therapeutic programmes. At the earliest stage of interest in a biological target we should be asking ‘what therapeutic modalities shall we apply?’ and both chemists and biologists are fundamental to the success of those strategic discussions, as well as the successful prosecution of the programme.

We are extremely grateful to the authors of the chapters in this book. They have not only described their areas of interest and expertise with great skill, but they have also shared compelling insights into the future opportunities for biotherapeutics. We also thank Rosalind Searle and Cara Sutton, RSC Publishing, for their editorial support and encouragement.

Lyn H. Jones and Andrew J. McKnight

Contents

Chapter 1	Synthetic Immunology	1
	<i>Thihan R. Padukkavidana, Patrick J. McEnaney and David A. Spiegel</i>	
1.1	Introduction and Scope	1
1.2	Synthetic Ligands for Pattern Recognition Receptors (PRRs)	2
1.2.1	Synthetic Mimics of TLR Ligands	2
1.2.2	Synthetic NOD Agonists	6
1.2.3	Peroxisome Proliferator-activated Receptor Gamma	8
1.2.4	C-Type Lectin Receptors (CLRs)	9
1.3	Synthetic Systems for Controlling Cell–Cell Communication: Cytokine Mimetics	10
1.4	Synthetic Molecules that Modulate the Complement System	13
1.5	Mimicking and Hijacking Antibody Function	15
1.6	Synthetic Molecules that Modulate T- and B-cell Responses	17
1.7	Concluding Remarks	22
	References	22
Chapter 2	Immunopharmacotherapy for Nicotine Addiction	36
	<i>Jonathan W. Lockner and Kim D. Janda</i>	
2.1	Introduction	36
2.2	Nicotine and the Body	37
2.3	Nicotine and the Brain	38
2.4	Nicotine and the Immune System	40

RSC Drug Discovery Series No. 36

Biotherapeutics: Recent Developments using Chemical and Molecular Biology

Edited by Lyn H. Jones and Andrew J. McKnight

© The Royal Society of Chemistry 2013

Published by the Royal Society of Chemistry, www.rsc.org

2.5	Nicotine and the Antibody	41
2.6	Preclinical Studies of Nicotine Immunopharmacotherapy	43
2.6.1	Janda	44
2.6.2	Pentel	45
2.6.3	Sanderson	46
2.6.4	Bunce/Bond/Aker	47
2.6.5	Maurer/Bachmann	47
2.6.6	Cerny	48
2.6.7	Svensson/de Villiers	48
2.6.8	Crystal	49
2.7	Clinical Trials of Nicotine Vaccines	49
2.7.1	Cytos Biotechnology AG	50
2.7.2	ImmuLogic/Cantab/Xenova/Celtic Pharma	50
2.7.3	Nabi Biopharmaceuticals/Biota Pharmaceuticals	51
2.7.4	Chilka Limited	51
2.7.5	Independent Pharmaceutica AB	52
2.7.6	Selecta Biosciences	52
2.7.7	Pfizer Vaccines Ltd	52
2.8	New Directions to Improve Immunogenicity	53
2.8.1	Carrier	54
2.8.2	Delivery Method	54
2.8.3	Adjuvants	55
2.8.4	Hapten Design	56
2.8.5	Caveat: No Nicotine Vaccine Should Be Viewed as a "Magic Bullet" Cure	57
2.8.6	Miscellany	58
2.9	Conclusions and Future Prospects	59
	Acknowledgements	60
	References	60

Chapter 3 Carbohydrate Vaccines 68

*Benjamin Schumann, Chakkumkal Anish,
Claney L. Pereira and Peter H. Seeberger*

3.1	Introduction	68
3.1.1	Cell Surface Glycans as Vaccine Candidates	69
3.1.2	Immunology of Carbohydrate-based Vaccines	72
3.1.3	Production and Manufacture of Glycoconjugate Vaccines	74
3.1.4	Opportunities and Challenges of Vaccines Based on Synthetic Oligosaccharides	77
3.2	Chemical Immunology of Glycoconjugate Vaccines	77
3.2.1	Effect of the Glycan on the Immune Response	78
3.2.1.1	Saccharide Length	78
3.2.1.2	Epitope Charge	79

3.2.1.3	Exposed Epitopes	80
3.2.1.4	Monosaccharide Modifications	82
3.2.2	Effects of Conjugation on the Immune Response	83
3.2.2.1	Conjugation Chemistry	83
3.2.2.2	Immunogenicity of Linker/Spacer Constructs	83
3.2.2.3	Antigen Density	83
3.2.2.4	T Cell Epitopes	84
3.2.2.5	Carrier Priming and Carrier-Induced Epitope Suppression	85
3.3	Novel Developments in Vaccine Design	86
3.3.1	Multicomponent Vaccines	86
3.3.2	Novel Carrier Platforms	87
3.3.3	Rational Vaccine Design	88
3.4	Conclusions	89
	Acknowledgements	90
	References	90

Chapter 4 Generation and Maturation of Therapeutic Antibodies via *In Vitro* Somatic Hypermutation **105**

David J. King

4.1	Antibodies as Therapeutic Agents	105
4.2	Approaches to the Generation of Therapeutic Antibodies	106
4.2.1	Recovery of Antibodies from <i>In Vivo</i> Sources	108
4.2.2	Recovery of Antibodies from <i>In Vitro</i> Sources	110
4.3	Mammalian Cell Display	113
4.4	Somatic Hypermutation (SHM)	117
4.5	Combining Mammalian Cell Display with <i>In Vitro</i> SHM	119
	References	123

Chapter 5 Synthetic Protein Biologics **130**

Benjamin G. Davis

5.1	Introduction and Strategy	130
5.1.1	Synthetic Biology as a Parallel to Synthetic Organic Chemistry	130
5.1.2	Synthetic Biology as the Driver for Chemical Medicine	132
5.1.3	Current Strategic Small-Mindedness and Opportunities Beyond It	133
5.1.4	Current Limitations Provide Further Opportunities	134

5.2	Synthetic Vaccines	135
5.3	Pegylation Technology and the Pegylation of Proteins	137
5.4	Synthetic Biologics with Payloads	139
5.5	Future Prospects and Conclusions	140
	References	142
Chapter 6	Recent Advances in Antibody–Drug Conjugates	145
	<i>Edmund I. Graziani and L. Nathan Tumey</i>	
6.1	Introduction	145
6.2	Recent Developments in ADC Linker Technology	146
6.2.1	Cleavable Linkers	146
6.2.2	Noncleavable Linkers	153
6.2.3	Impact of Linkers on Biophysical Properties	155
6.3	Recent Developments in Site Specific Conjugation of ADCs	156
6.3.1	Engineered Cysteines	157
6.3.2	Unnatural Amino Acids as Reactive Handles for Antibody Conjugation	160
6.3.3	Chemical and Enzymatic Methods for Site-Specific Protein Conjugation	162
6.4	Recent Developments in ADC Metabolism and PK	164
6.4.1	Payload Release In Targeted Tissues	165
6.4.2	Premature Payload Release In Circulation And Non-Targeted Tissues	166
6.4.3	Pharmacokinetics/Pharmacodynamics	167
6.4.4	ADC Clearance and Elimination	168
6.5	Summary and Future Prospects	169
	References	170
Chapter 7	MicroRNA Biotherapeutics: Key Challenges from a Drug Development Perspective	176
	<i>Sterghios Athanasios Moschos</i>	
7.1	Introduction	176
7.2	MicroRNA Biogenesis	180
7.2.1	Genomic Organization of Endogenous miRNAs	181
7.2.2	Virus-Encoded miRNAs	182
7.2.2.1	Herpesviruses	182
7.2.2.2	Adenovirus	183
7.2.2.3	RNA Viruses: an Unlikely, yet Flexible Group of Vectors	183
7.2.3	Canonical miRNA Maturation	184
7.2.3.1	Excision of miRNA Precursors from Primary Transcripts	185
7.2.3.2	Nuclear Export of Pre-miRNAs	186

7.2.3.3	Removal of the Hairpin Loop	186
7.2.3.4	Selection and Loading to Effector Protein Complexes	187
7.2.3.5	Guide Strand Selection	188
7.2.4	EXP5 and Safety of Ectopic RNAi Mediator Expression	189
7.2.5	Alternative Maturation Pathways	190
7.2.5.1	Mirtrons and Simtrons	190
7.2.5.2	miRNAs Encoded in Small Nucleolar RNAs	192
7.2.5.3	miR-451	193
7.2.5.4	miRNA Offset RNAs	193
7.2.5.5	Viral Lessons on RNAi Precursor Maturation	194
7.2.6	Post-Transcriptional Processing of miRNAs	195
7.3	miRNA Function	198
7.3.1	Molecular Actions of miRNAs: Therapeutic Challenges and Opportunities	198
7.3.1.1	Ago2-Mediated Translational Repression	198
7.3.1.2	Slicer-Independent Translational Repression	200
7.3.1.3	Other Mechanisms of miRNA Action	204
7.4	Concluding Remarks: the Impact of the Developing miRNA Knowledge Base on Biotherapeutics Development Efforts	207
	References	209

Chapter 8 Novel Therapeutic Agents from Bacterial Toxins **224**

John A. Chaddock

8.1	Introduction	224
8.2	Therapeutic Opportunities from Cytotoxic Bacterial Toxins	226
8.2.1	Pre-Clinical Studies with Cytotoxic Bacterial Toxin Domains	226
8.2.1.1	Diphtheria Toxin-Based Opportunities	226
8.2.1.2	Pseudomonas Exotoxin-Based Opportunities	227
8.2.2	Clinical Application of Cytotoxic Bacterial Toxin Domains	228
8.3	Therapeutic Opportunities from Non-Cytotoxic Bacterial Toxins	229
8.3.1	Clinical Application of Natural Toxin Products	229

8.3.2	The Domain Structure of BoNT as a Template for New Product Engineering	231
8.3.3	Utilising Toxin Domains to Deliver Therapeutic Cargo	232
8.3.4	Harnessing the Properties of Clostridial Neurotoxin Domains in Engineered Hybrids	233
8.3.4.1	Creation of Improved Product Opportunities	233
8.3.5	Targeted Secretion Inhibitors	234
8.3.5.1	Concept and Potential	234
8.3.5.2	Implementing the Concept at the Research Phase	234
8.3.5.3	Development of Recombinant TSI	235
8.3.5.4	Pre-Clinical Evidence of TSI Development	236
8.3.5.5	Targeted Secretion Inhibitors in the Clinic	237
8.4	Conclusions	238
	References	239
Chapter 9	Phage Selection of Mono- and Bicyclic Peptide Ligands	241
	<i>Shiyu Chen and Christian Heinis</i>	
9.1	Introduction	241
9.2	Phage Selection of Monocyclic Peptides	242
9.2.1	Phage Display Systems	242
9.2.2	Disulfide-Cyclized Peptide Phage Libraries	245
9.2.3	Phage Panning of Disulfide-Cyclized Peptide Libraries	246
9.3	Examples of Phage-Selected Monocyclic Peptides	247
9.3.1	Ligands of Vascular Endothelial Growth Factor	247
9.3.2	Cyclic Peptide Erythropoietin Receptor Agonists	248
9.4	Phage Selection of Bicyclic Peptides	250
9.4.1	Bicyclic Peptides	250
9.4.2	Bicyclization of Peptides on Phage	252
9.4.3	Bicyclic Peptide Phage Libraries	252
9.4.4	Phage Panning of Bicyclic Peptide Phage Libraries	254
9.5	Examples of Phage-Selected Bicyclic Peptides	254
9.5.1	Inhibitors of Plasma Kallikrein	255
9.5.2	Inhibitors of Urokinase-Type Plasminogen Activator	256
9.6	Conclusions	257
	Acknowledgments	258
	References	258

Chapter 10 Chemical Approaches for Localization, Characterization and Mimicry of Peptide Epitopes	263
<i>Paul R. Werkhoven and Rob M.J. Liskamp</i>	
10.1 Introduction, Definitions and Different Types of Epitopes	263
10.2 Shape and Structure of Epitopes	266
10.3 Determination of the Primary, Secondary or Tertiary Structure of Epitopes	268
10.4 Applications of Peptide Epitope Mimics	270
10.4.1 Epitope Mimics as Synthetic Vaccines	270
10.4.2 Epitope Mimics as Inhibitors (Antagonists) of Protein–Protein Interactions	271
10.4.3 Paratope Mimics as Synthetic Antibodies	271
10.5 Mimicry of Epitopes by Peptides	272
10.5.1 Single Linear Peptides as Continuous Epitope Mimics	272
10.5.2 Constraining Peptides for Optimization of Structural Mimicry	272
10.5.3 Assembly of Peptides for Mimicry of Discontinuous Epitopes	274
10.5.3.1 Assembly of Peptides by the Preparation of Dimers or Multimers	275
10.5.3.2 Assembly of Peptides by Scaffolding	275
10.5.3.3 Scaffolds	276
10.5.4 Requirements for Discontinuous Epitope Containing Protein Mimics	277
10.6 Conclusions	278
References	278
 Chapter 11 Cystine-Knot Micro-Proteins	 285
<i>Bill Eldridge, Simon Robins and Duncan McGregor</i>	
11.1 Cystine-Knot Micro-Proteins	285
11.1.1 Conotoxins and Venom-Derived CK Micro-Proteins	286
11.1.2 Human CK Micro-Proteins	287
11.1.3 Plant-Derived CK Micro-Proteins	287
11.2 Use as Scaffolds	288
11.2.1 Loop Grafting	288
11.2.2 Display Libraries Using Loop Replacement	288

11.2.3	MCOTI-II as a Loop Replacement Scaffold	289
11.3	Stability of Selected CK Micro-Proteins	290
11.4	Potential Therapeutic Applications of CK Micro-Proteins	293
	References	294
	Subject Index	298

CHAPTER 1

Synthetic Immunology

THIHAN R. PADUKKAVIDANA,^{a,†}
PATRICK J. MCENANEY^{a,†} AND DAVID A. SPIEGEL^{*a,b}

^aDepartment of Chemistry, Yale University, 225 Prospect Street,
PO Box 208107, New Haven, CT 06520-8107, USA; ^bDepartment of
Pharmacology, Yale University School of Medicine, 333 Cedar Street,
SHM B350B, New Haven, CT 06520, USA

*Email: david.spiegel@yale.edu

1.1 Introduction and Scope

The field of immunology has become increasingly lucid at the level of atoms and molecules. Owing also to advances in synthetic chemistry, the rational design and construction of synthetic systems that perform complex immunological functions – an area termed synthetic immunology – has come within reach. Here we will highlight one facet of synthetic immunology concerned with the development of low-molecular weight (“small”), synthetic molecules that are capable of functionally mimicking biological molecules. It is important to note at the outset that this article does not aim to be comprehensive in scope. At the expense of being all-inclusive, we focus on several specific contributions, which highlight how advances in immunology and chemistry have proven mutually complementary. We have divided this chapter into four subsections: (1) synthetic ligands for pattern recognition receptors, including toll-like receptors (TLRs), NOD-like receptors (NLRs), nuclear family receptors and C-type lectins, (2) synthetic molecules that modulate the complement system,

[†]These authors contributed equally to this work.

(3) synthetic systems for controlling cell–cell communication, including chemokine/cytokine mimetics, and (4) synthetic ligands for modulating adaptive immune processes, including T-cell and B-cell functions.

We regret not being able to cover all of the exciting developments that might be classified into the area of Synthetic Immunology. Such areas include: synthetic vaccine development, as this topic is covered elsewhere in this book;¹ synthetic modulators of cellular signaling processes, as the functions of such molecules extend beyond the immune system;^{2–5} protein-based and cellular immunotherapies, including therapeutic monoclonal antibodies;^{6–9} immunomodulator strategies involving nanoparticles or virus-like particles;^{10–13} DNA- and RNA-based therapeutics;^{14–16} and strategies for controlling cellular differentiation.^{17–20} Lead references to each of these areas are provided for interested readers.

It is our hope that this chapter will serve as a broad-based introduction for biomedical scientists, including chemists interested in extending their activities into the immunological realm, as well as immunologists looking to learn about how modern synthetic chemistry can enhance fundamental biological understanding. Ultimately, we believe that the intellectual perspective residing at the interface between synthetic chemistry and immunology will enable scientific advances that were never before thought possible, thus proving critical to the furtherance of basic biomedical research and patient care.

1.2 Synthetic Ligands for Pattern Recognition Receptors (PRRs)

Pattern recognition receptors (PRRs) are a diverse class of proteins that function canonically as part of the innate immune response. These receptors recognize pathogen-associated molecular patterns (PAMPs), which are widely conserved, repeating motifs found within pathogens and not within hosts, as well as damage-associated molecular patterns (DAMPs), which are host-derived molecules that arise from tissue damage.^{21,22} Improper activation of these receptors has been shown to cause hyper-inflammatory disease states, and extensive research efforts have focused on identifying PRR antagonists. Such developments have been reviewed elsewhere.^{23–33} In this section we discuss a few select examples of molecules that functionally mimic the natural ligands of PRRs.

1.2.1 Synthetic Mimics of TLR Ligands

Toll-like receptors (TLRs) were originally discovered as important receptors for *Drosophila melanogaster* embryonic development,³⁴ and were later found to play a critical role in innate immunity in humans.³⁵ Extensive research during the past two decades has revealed the TLR superfamily to contain more than ten different family members (TLRs 1–13).²²